Sage Journals: Discover world-class research

Abstract

Spanish

French

Objective:

To evaluate lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome (MDS).

Data Sources:

Clinical literature was accessed through MEDLINE (1966–August 2005), Science Citation Index (1980–August 2005), and Proceedings of the American Society of Hematology (2000–2004).

Data Synthesis:

New analogs of thalidomide have been synthesized that are more potent and less toxic. Lenalidomide (CC-5013) is currently in Phase III trials for the treatment of multiple myeloma and MDS. Phase II trials demonstrated lenalidomide's efficacy in patients refractory to thalidomide. The full potential of this agent has yet to be proven, but preliminary data seem promising.

Conclusions:

Lenalidomide is a potent immunomodulating drug that offers different mechanisms of action and therapeutic potential for the treatment of multiple myeloma, MDS, and other malignancies.

Keywords

lenalidomide multiple myeloma myelodysplastic syndrome thalidomide

Get full access to this article

View all access options for this article.

References

Bartlett

Dredge

Dalgleish

. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Natl Rev Cancer 2004;4:314–22.

Haslett

Hanekom

Muller

Kaplan

. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 2003;187:946–55.

Sleijfer

Kruit

Stoter

. Thalidomide in solid tumours: the resurrection of an old drug. Eur J Cancer 2004;40:2377–82.

Dredge

Dalgleish

Marriott

. Thalidomide analogs as emerging anti-cancer drugs. Anticancer Drugs 2003;14:331–5.

Marriott

Clarke

Dredge

Muller

Stirling

Dalgleish

. Thalidomide and its analogues have distinct and opposing effects on TNF-α and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells. Clin Exp Immunol 2002;130:75–84.

Richardson

Anderson

. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol 2004;22:3212–4.

Schafer

Gandhi

Loveland

. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003;305:1222–32.

Dredge

Marriott

Macdonald

. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002;87:1166–72.

Koh

Janz

Mapara

. Immunomodulatory derivative of thalidomide (IMid CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood 2003;105:3833–40.

10.

Sirohi

Powles

. Multiple myeloma. Lancet 2004;363:875–87.

11.

Kyle

Rajkumar

. Multiple myeloma. N Engl J Med 2004;351:1860–73.

12.

Barlogie

Shaughnessy

Tricot

. Treatment of multiple myeloma. Blood 2004;103:20–32.

13.

Richardson

Schlossman

Weiler

. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063–7.

14.

Richardson

Jagannath

Schlossman

. A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of two CC-5013 dose regimens when used alone or in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma (MM) (abstract). Blood 2003;102:235a.

15.

Schey

Fields

Bartlett

. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22:3269–76.

16.

Fenaux

. Myelodysplasie syndromes: from pathogenesis and prognosis to treatment. Semin Hematol 2004;41:6–12.

17.

Raza

Meyer

Dutt

. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplasia syndromes. Blood 2001;98:958–65.

18.

List

Kurtin

Roe

. Efficacy of lenalidomide in myelodysplasia syndromes. N Engl J Med 2005;352:549–57.

19.

Bartlett

Michael

Clarke

. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004;90:955–61.

Role of Lenalidomide in the Treatment of Multiple Myeloma and Myelodysplasic Syndrome

Abstract

Objective:

Data Sources:

Data Synthesis:

Conclusions:

Keywords

Get full access to this article

References